Vermillion Renews Strategic Alliance Agreement with Quest Diagnostics
News Oct 30, 2008
Vermillion, Inc. has announced that it has agreed with Quest Diagnostics to extend the Strategic Alliance Agreement between the parties through October, 2009.
This extension will enable the companies to continue work on the development and commercialization of two tests, OVA1™ and VASCLIR™.
The OVA1 test is intended to identify women with ovarian tumors that are at high risk of being malignant. Data from a 27-site, 511 subject prospective clinical trial were submitted to the FDA in June of this year in a 510(k) premarket notification. Vermillion's 510(k) premarket notification submission is currently pending before the FDA.
To date, Vermillion and the FDA have had several substantive discussions regarding the submission. Vermillion is encouraged by the constructive nature of these discussions and by the interactive review process with the FDA. Vermillion believes that it will be able to provide information and data to the FDA that will respond to the FDA's questions during this quarter.
Additionally, this week Vermillion presented preliminary data from its OVA1 prospective clinical trial at the International Gynecologic Cancer Society's 12th Biennial Meeting.
The oral presentation, "A Biomarker Panel for Distinguishing Between Malignant and Benign Ovarian Tumors" was co-authored by scientists at Vermillion, Dr. Fred Ueland, Associate Professor of Gynecologic Oncology at the University of Kentucky and Principal Investigator of the OVA1 trial, and Dr. Zhen Zhang, Associate Professor of Pathology at Johns Hopkins University School of Medicine.
VASCLIR is a test designed to aid physicians in identifying those patients who are at high risk of developing peripheral artery disease. Vermillion is developing this test in collaboration with Dr. John Cooke at Stanford University. Results from a 540 subject validation study were recently published in the peer-reviewed journal, Vascular Medicine.
"Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and we are very excited to continue this relationship," said Gail S. Page, CEO and President of Vermillion.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
CBD Significantly Reduces Seizures in Patients with Severe Form of EpilepsyNews
Large-scale clinical trial finds cannabidiol can dramatically reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.
New Approach to Cancer Research Aims to Accelerate Studies and Reduce CostNews
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018